2025 Q4 -tulosraportti
Vain PDF
84 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 000 | - | - | ||
| 26 789 | - | - | ||
| 273 211 | - | - | ||
| 26 789 | - | - | ||
| 1 218 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 24.6. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 | ||
2024 Q4 -tulosraportti 26.3.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 t sitten"Broad spectrum inhaled countermeasure against respiratory biological threats" sounds more relevant in 2026 than it did a few years ago. Europe must build CBRN and biosecurity preparedness, the Russia risk is increasing, and AI/biosecurity fear makes biological threats more concrete. This makes SIS/COUNTERACT more strategically relevant. The military track has come a long way, animal trials are already completed or near completion internally. Testing started in autumn 2024, results were expected in 2025, and SoftOx has already reported preliminary/good efficacy signals in several models. SoftOx/partners have had plenty of time for testing in animal models: Testing was initiated in autumn 2024 Q4 2024 said results were expected in 2025 Q2/Q3 2025 already reported: good efficacy in murine P. aeruginosa model good efficacy in murine influenza model “great efficacy” against several relevant respiratory pathogens, incl. Bacillus anthracis, ANTHRAX! Q4 2025 still said “being conducted”, but with preliminary promising results against: Pseudomonas aeruginosa Streptococcus pneumoniae Klebsiella pneumoniae influenza. The human trials in Ireland are underway, so we can assume good results from the animal testing. So by June 2026, it is entirely reasonable to assume that much more has been done behind closed doors than the market gets to see in the stock exchange announcements. The military track is the biggest reason I am invested.
·19 t sittenIt is easy to become impatient when the stock price does not go the way one wishes, but it is worth reminding oneself what SoftOx has actually achieved in recent months. ✅ SIS-03 has completed the dose escalation part without reported safety issues. ✅ Proof-of-concept phase 2a in cystic fibrosis has now started, where a reduction in bacterial load in the airways will be sought. ✅ SoftOx is developing a local, non-antibiotic treatment for chronic respiratory infections – an area with great medical need. ✅ Antibiotic resistance is a growing global problem, and alternative forms of treatment are something both authorities and healthcare systems demand. ✅ The company has several programs under development and is no longer just an idea on the drawing board. The market often focuses on today's price. I prefer to focus on where the company could be in 6–18 months if the clinical results continue to be positive. Biotech is never risk-free, but as of today, I see a company that actually delivers on its milestones and moves forward step by step. Everyone must make their own assessments, but I think it is important to remember that the value in a biotech company is often created long before the market discovers it.
·21 t sittenThis is a silly story and completely irrelevant, but quite funny. I had a severe skin infection and used a Softox spray 5 years past its expiration date to heal it. It caused no problems. Even though Softox Solutions is about powder, it's essentially the same thing. So who knows, maybe it's relevant after all.....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
84 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sitten"Broad spectrum inhaled countermeasure against respiratory biological threats" sounds more relevant in 2026 than it did a few years ago. Europe must build CBRN and biosecurity preparedness, the Russia risk is increasing, and AI/biosecurity fear makes biological threats more concrete. This makes SIS/COUNTERACT more strategically relevant. The military track has come a long way, animal trials are already completed or near completion internally. Testing started in autumn 2024, results were expected in 2025, and SoftOx has already reported preliminary/good efficacy signals in several models. SoftOx/partners have had plenty of time for testing in animal models: Testing was initiated in autumn 2024 Q4 2024 said results were expected in 2025 Q2/Q3 2025 already reported: good efficacy in murine P. aeruginosa model good efficacy in murine influenza model “great efficacy” against several relevant respiratory pathogens, incl. Bacillus anthracis, ANTHRAX! Q4 2025 still said “being conducted”, but with preliminary promising results against: Pseudomonas aeruginosa Streptococcus pneumoniae Klebsiella pneumoniae influenza. The human trials in Ireland are underway, so we can assume good results from the animal testing. So by June 2026, it is entirely reasonable to assume that much more has been done behind closed doors than the market gets to see in the stock exchange announcements. The military track is the biggest reason I am invested.
- ·19 t sittenIt is easy to become impatient when the stock price does not go the way one wishes, but it is worth reminding oneself what SoftOx has actually achieved in recent months. ✅ SIS-03 has completed the dose escalation part without reported safety issues. ✅ Proof-of-concept phase 2a in cystic fibrosis has now started, where a reduction in bacterial load in the airways will be sought. ✅ SoftOx is developing a local, non-antibiotic treatment for chronic respiratory infections – an area with great medical need. ✅ Antibiotic resistance is a growing global problem, and alternative forms of treatment are something both authorities and healthcare systems demand. ✅ The company has several programs under development and is no longer just an idea on the drawing board. The market often focuses on today's price. I prefer to focus on where the company could be in 6–18 months if the clinical results continue to be positive. Biotech is never risk-free, but as of today, I see a company that actually delivers on its milestones and moves forward step by step. Everyone must make their own assessments, but I think it is important to remember that the value in a biotech company is often created long before the market discovers it.
- ·21 t sittenThis is a silly story and completely irrelevant, but quite funny. I had a severe skin infection and used a Softox spray 5 years past its expiration date to heal it. It caused no problems. Even though Softox Solutions is about powder, it's essentially the same thing. So who knows, maybe it's relevant after all.....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 000 | - | - | ||
| 26 789 | - | - | ||
| 273 211 | - | - | ||
| 26 789 | - | - | ||
| 1 218 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 24.6. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 | ||
2024 Q4 -tulosraportti 26.3.2025 |
2025 Q4 -tulosraportti
Vain PDF
84 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 24.6. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 | ||
2024 Q4 -tulosraportti 26.3.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sitten"Broad spectrum inhaled countermeasure against respiratory biological threats" sounds more relevant in 2026 than it did a few years ago. Europe must build CBRN and biosecurity preparedness, the Russia risk is increasing, and AI/biosecurity fear makes biological threats more concrete. This makes SIS/COUNTERACT more strategically relevant. The military track has come a long way, animal trials are already completed or near completion internally. Testing started in autumn 2024, results were expected in 2025, and SoftOx has already reported preliminary/good efficacy signals in several models. SoftOx/partners have had plenty of time for testing in animal models: Testing was initiated in autumn 2024 Q4 2024 said results were expected in 2025 Q2/Q3 2025 already reported: good efficacy in murine P. aeruginosa model good efficacy in murine influenza model “great efficacy” against several relevant respiratory pathogens, incl. Bacillus anthracis, ANTHRAX! Q4 2025 still said “being conducted”, but with preliminary promising results against: Pseudomonas aeruginosa Streptococcus pneumoniae Klebsiella pneumoniae influenza. The human trials in Ireland are underway, so we can assume good results from the animal testing. So by June 2026, it is entirely reasonable to assume that much more has been done behind closed doors than the market gets to see in the stock exchange announcements. The military track is the biggest reason I am invested.
- ·19 t sittenIt is easy to become impatient when the stock price does not go the way one wishes, but it is worth reminding oneself what SoftOx has actually achieved in recent months. ✅ SIS-03 has completed the dose escalation part without reported safety issues. ✅ Proof-of-concept phase 2a in cystic fibrosis has now started, where a reduction in bacterial load in the airways will be sought. ✅ SoftOx is developing a local, non-antibiotic treatment for chronic respiratory infections – an area with great medical need. ✅ Antibiotic resistance is a growing global problem, and alternative forms of treatment are something both authorities and healthcare systems demand. ✅ The company has several programs under development and is no longer just an idea on the drawing board. The market often focuses on today's price. I prefer to focus on where the company could be in 6–18 months if the clinical results continue to be positive. Biotech is never risk-free, but as of today, I see a company that actually delivers on its milestones and moves forward step by step. Everyone must make their own assessments, but I think it is important to remember that the value in a biotech company is often created long before the market discovers it.
- ·21 t sittenThis is a silly story and completely irrelevant, but quite funny. I had a severe skin infection and used a Softox spray 5 years past its expiration date to heal it. It caused no problems. Even though Softox Solutions is about powder, it's essentially the same thing. So who knows, maybe it's relevant after all.....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 000 | - | - | ||
| 26 789 | - | - | ||
| 273 211 | - | - | ||
| 26 789 | - | - | ||
| 1 218 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt